Glanzmann Thrombasthenia Clinical Trial
Official title:
Glanzmann Thrombasthenia Natural History Study+
Glanzmann thrombasthenia is a rare autosomal recessive platelet disorder characterized by a lack of functional integrins alfaIIb or beta3 (glycoproteins IIb/IIIa). The prevalence is variously reported to be between 1:200,000 to 1:1,000,000, with substantial geographic variation. The clinical phenotype is dominated by an increased mucocutaneous bleeding tendency. In absence of a primary bleeding prophylaxis, the current treatment of Glanzmann thrombasthenia is mainly focused on prevention or management of bleeding. However, as potential new therapies emerge, clinicians require unbiased, long-term safety and efficacy data for both current treatment and new therapies. We have designed this study to investigate genetic phenotype (ITGA2B and ITGB3 genes) and the prevalence of antibodies against human leucocyte antigen (HLA) and human platelet antigen (HPA), the latter two being a potential consequence of the current golden standard treatment: platelet transfusion. The results of this study will be merged with a longitudinal registry with retrospective and prospective data collection of clinical phenotype, haemorrhagic burden and bleeding management. Analysis of the data from the Glanzmann-NHS+ study and the registry will help us to get a better understanding of the clinical variation among participants with Glanzmann thrombasthenia. The ultimate goal is to accelerate improvement in the care of patients with Glanzmann thrombasthenia.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01319851 -
Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation
|
N/A | |
| Recruiting |
NCT00230165 -
The Genetics and Functional Basis of Inherited Platelet, White Blood Cell, Red Blood Cell, and Blood Clotting Disorders.
|
||
| Recruiting |
NCT02179359 -
Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies
|
N/A | |
| Recruiting |
NCT04119908 -
Videomicroscopy for the Prediction of Bleeding in Constitutional Haemorrhagic Diseases
|
N/A | |
| Terminated |
NCT04548791 -
Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders
|
Phase 1/Phase 2 | |
| Completed |
NCT04595617 -
Anti-αIIbβ3 Immunization in Glanzmann Thrombasthenia: Prevalence and Associated Risk Factors: Thrombasthenia Anti-αIIbβ3 Antibodies Study (TAAS)
|
N/A | |
| Completed |
NCT01917708 -
Bone Marrow Transplant With Abatacept for Non-Malignant Diseases
|
Phase 1 | |
| Active, not recruiting |
NCT03333486 -
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
|
Phase 2 | |
| Recruiting |
NCT06211634 -
A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia
|
Phase 1/Phase 2 | |
| Completed |
NCT06234813 -
Targeting TFPI With Concizumab to Improve Haemostasis in Glanzmann Thrombasthenia Patients: an in Vitro Study
|
N/A | |
| Completed |
NCT05315232 -
The Experiences of People Who Live With Glanzmanns Thrombasthenia.
|